Immunocore: Detailed Review of Tebentafusp (IMCgp100) in Metastatic Uveal Melanoma Published in Issue of Cancers

(Oxfordshire, UK and Pennsylvania and Maryland, US, 16 July 2019) Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announce the publication of “Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma” in a special issue on uveal melanoma in Cancers, an international, peer-reviewed monthly journal.[i] Written by Dr. Bertil Damato, Dr. Richard Carvajal and experts at Immunocore, the paper provides an overview of the biology of uveal melanoma, the use of immunotherapy to treat metastatic disease and reviews tebentafusp, an investigational agent being studied for the treatment of metastatic uveal melanoma.